FindTrial
Sign In

eFT508

DRUG4 trials

Sponsors

Effector Therapeutics

Conditions

CancerCastrate-resistant Prostate Cancer (CRPC)Hepatocellular CarcinomaMicrosatellite Stable Relapsed or Refractory Colorectal CancerTriple Negative Breast Cancer

Phase 1

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
TerminatedNCT02605083
Effector TherapeuticsCancer
Start: 2015-12-03End: 2019-03-22Updated: 2020-11-02

Phase 2

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
CompletedNCT03258398
Effector TherapeuticsMicrosatellite Stable Relapsed or Refractory Colorectal Cancer
Start: 2017-09-18End: 2019-05-13Updated: 2019-07-18
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
TerminatedNCT03318562
Effector TherapeuticsHepatocellular Carcinoma, Triple Negative Breast Cancer
Start: 2017-11-21End: 2019-01-22Updated: 2019-07-18
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
TerminatedNCT03690141
Effector TherapeuticsCastrate-resistant Prostate Cancer (CRPC)
Start: 2018-11-27End: 2020-04-27Updated: 2024-06-21

Related Papers

A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
Journal of Clinical Oncology2019-05-209 citations
A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors.
Journal of Clinical Oncology2017-05-2015 citations